医学
心力衰竭
重症监护医学
射血分数保留的心力衰竭
糖尿病
射血分数
内科学
人口
不利影响
心脏病学
环境卫生
内分泌学
作者
Jonathan Ch Chan,Abdul Hasan Siddiqui
出处
期刊:Current Cardiology Reviews
[Bentham Science]
日期:2024-01-26
卷期号:20
标识
DOI:10.2174/011573403x270178231228061314
摘要
Heart failure is a clinical condition with high mortality and morbidity that occurs when the heart is unable to pump enough blood to meet the metabolic demands of the body. The pharmacological management of heart failure has been revolutionized over the past decade with novel treatments.The aim of the review is to highlight the recent pharmacological advances in the management of heart failure.Sodium-glucose cotransporter-2 inhibitor (SGLT2i), iron carboxymaltose, finerenone, omecamtiv mecarbil, and vericiguat have been shown to reduce hospitalization for heart failure. However, only SGLT2i, vericiguat, and omecamtiv mecarbil have been shown to reduce cardiovascular death. Finerenone has been shown to reduce cardiovascular events and renal adverse outcomes in patients with diabetes and kidney disease. Currently, only SGLT2i has been studied in patients beyond the heart failure-reduced ejection fraction population.The current quadruple therapy in the treatment of heart failure has demonstrated a reduction in the hospitalization of patients and a decrease in mortality associated with the condition. Individualized heart failure therapy research have shown some benefit in select heart failure patients. Further research on novel therapies will help improve heart failure patient outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI